PATENT CLAIM ANALYSIS

Application Number: 15780398
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-12
Patent Classification: ["514", "275000"]

Abstract:
The disclosure includes a method of inducing direct reprogramming (transdifferentiation) into non-oncogenic cells accompanied by tumor cell apoptosis in human tumor cells using a small molecule composition, based on the mechanism of chemical-induction of direct cellular reprogramming. The disclosure also includes a small molecule composition used for the method, and culture media and agents prepared from the composition.

Claim (Index 6):
The composition of any one of  claims 1 - 5 , wherein,\n the GSK3\u03b2 inhibitor includes a GSK3\u03b2 signaling pathway inhibitor or a compound of the same class that have the same function or target the same induction site(s), as represented by CHIR-99021, BIO, IM-12, TWS119, 1-Azakenpaullone, CHIR-98014, Tideglusib, AR-A014418, LY2090314, SB216763, AZD1080, or a functionaly equivalent pharmaceutical preparation, analogue, isomer and/or salt, hydrate or precursor thereof, or a combination thereof; preferably, GSK3\u03b2 inhibitor CHIR-99021; the TGF\u03b2 inhibitor includes a TGF\u03b2 signaling pathway inhibitor or a compound of the same class that have the same function or target the same induction site(s), as represented by SB431542, A83-01, SB525334, LY2109761, RepSox, SD-208, GW788388, SB505124, EW-7197, or a functionally equivalent pharmaceutical preparation, analogue, isomer and/or salt, hydrate or precursor thereof, or a combination thereof; preferably, TGF\u03b2 inhibitor SB431542 or/and A83-01; the retinoid compound is a naturally occurring one or an artificially synthesized one, and includes a retinoid differentiation-inducing agent or a compound of the same class that have the same function or target the same induction site(s), as represented by retinoic acid, 13-cis retinoic acid, 9-cis retinoic acid, isotretinoin, etc., or a functionally equivalent pharmaceutical preparation, analogue, isomer and/or salt, hydrate or precursor thereof, or a combination thereof; preferably, retinoic acid; the BMP inhibitor includes a BMP signaling pathway inhibitor or a compound of the same class that have the same function or targeting the same inductive site, as represented by LDN-193189, K02288, DMH1, etc., or a functionally equivalent pharmaceutical preparation, analogue, isomer and/or salt, hydrate or precursor thereof, or a combination thereof; preferably, BMP inhibitor LDN-193189.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 93.0
- Lexical Diversity: 1.48837
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13697274', '15376536', '13704214', '15446552', '15072769']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7785892752010909
- 35 USC 102 Novelty (BERT): 0.5136596873222324
- Combined Prediction Score: 0.7520963164132051
- Mean Citation Score: 247.068706
- Max Citation Score: 257.53943
- Similarity Product: 160.35671820626257

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test